ZGNX:p values of phase III exterminate short positions
I knew this for a long time, but decided to post this data the week before Adcom as where it was a nuclear bomb to destroy all shorts.
To start: Statistically all p values under p=.05 are significant. The lower the p value the better.
For Zohydro: 1. primary endpoint: chronic pain relief vs placebo based on average mean changes in daily pain intensity (Numeric Rating Scale) p=.008
2. secondary endpoint: 2A. Responder Rate Analysis: Significantly higher proportion of patients (%) experiencing improvement in pain relief from beginning to end of study more than 30% improvement (p<.001!!!!) more than 50% improvement (p<.001!!!!) more than 70% improvement (p<.05)
2B. Subject Global Assessment of Medication : Significantly improved overall satisfaction (p<0.001)